Search results
Results From The WOW.Com Content Network
The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values).
Dec. 2—Pfizer Inc. is starting to roll out the pharmaceutical company's biggest round of layoffs since 2009, and its Groton laboratories are not immune. Of course, New York-based Pfizer these ...
In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. [24] In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion. [25]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
There’s also evidence that workers are quitting somewhat less than they did in 2021 and the first half of last year. Workers tend to get the biggest bump up in pay when they change jobs.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Pharmaceuticals are a tricky business. Public policy, science, R&D;, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.But some Big Pharma ...
The company expects to be profitable in 2025. [ 2 ] In July 2023 due to a disappointing sales ramp-up of the recently approved sleep drug daridorexant , coupled with disappointing trial results in both clazosentan and lucerestat , Idorsia announced layoffs of up to five hundred staff of its one thousand two hundred total employees, to reduce ...